Studies of Survival in Chronic-Phase CML Patients Undergoing Allogeneic BMT With Matched Related Donors
| Authors, Year . | No.6-150 . | Population Description . | Protocol . | Med f-u (mo) . | Outcomes (95% CI) for CP Patients . | Years of f-u . | |||
|---|---|---|---|---|---|---|---|---|---|
| Conditioning Regimen . | GVHD Prophylaxis . | Relapse6-151 Rate (%) . | Overall Survival mo . | Disease-Free Survival mo . | |||||
| Goldman et al,86 19936-163 | 450 | CP-Ph+, med age NR (EST = 30 s), 10 mo (med) from dx, prior rx = HU/BUS | Cy + TBI Cy + BUS | CsA MTX | NR | 9-14 (2-51)6-152 | 45-67 (26-82)6-153 | 41-65 (21-80)6-155 | 3 |
| Goldman et al,72 19886-163 | 405 | Ph status NR, med age NR, mo from dx NR, prior rx NR | “chemo” + TBI | CsA TCD MTX “steroids” | 25 | 19 (12-28) | 55 (50-60) | 46 (40-52) | 4 |
| van Rhee et al,571997 | 373 | Ph status NR, med age = 31, 42%, 1 yr from dx, prior rx NR | Cy + TBI | CsA Pred MTX | 84 | 19 (14-25) 10 (7-15) | 54 (49-59) | 47 (41-52) | 8 2 |
| Thomas et al 1986,71 1989108 | 67/190 | Ph+, med age NR (EST = 30), mo from dx NR, 19% prior BUS | Cy + TBI | CsA MTX TCD | NR | 24 (NR) | 49 (NR) 65 (NR) | — | NR |
| Devergie et al,87 1990 | 170 | Ph status NR, med age NR (EST = low 30s), 21 mo (med) from dx, 67% prior splenectomy | Cy + TBI | CsA TCD MTX | 44 | 19% (NR) | 56 (NR) | 46 (NR) | NR |
| Clift et al,68 1994 | 142 | Ph+, mean age 37-39, 71% <1 yr from dx, 93% prior rx | Cy + TBI Cy + BUS | CsA MTX | NR | NA | 80 (NR) | 68-71 (NR) | 3 |
| Beelen et al,93 1995 | 135 | Ph+, med age = 33, 16-25 mo from dx, 61% prior HU/BUS, 37% rIFN-α | Cy + TBI | CsA MTX Antibiot | 59 | 17 (7-27) | 55 (51-59) | 49 (44-54) | 5 |
| Clift et al,102 1991 | 116 | Ph+, med age NR (EST = 30s), 66% <1 yr from dx, 4-78% prior HU/BUS/rIFN | Cy + TBI | CsA MTX Pred | NR (>12) | 0-19 (0-32) 0-25 | 69-82 (57-92) 66-73 (54-86) 60-666-154 | 58-66 (NR) | 1 3 4 |
| Snyder et al,1041988 | 94 | Ph+ (99%), med age = 34, 7 mo (med) from dx, >64% prior HU, BUS, rIFN-α, other | VP-16 + TBI | CsA Pred MTX | 31 | 14 (7-26) | 73 (61-81) | 64 (52-74) | 5 |
| Wagner et al,821992 | 79 | Ph status NR, med age NR, 7-16 mo from dx, 94% prior HU, BUS, rIFN-α | Cy + TBI | CsA Mpred Cy TCD | NR | 16 (6-37)# | 52 (NR) | 54 (37-68)6-160 | 5 |
| Brodsky et al,83 1993 | 62 | Ph+, med age = 35, 10 mo (med) from dx, prior rx NR | Cy + BUS | CsA Mpred MTX | NR | 3 (2-3) | 58 (46-70) | 58 (46-70) | NR |
| Storb et al,70 1989 | 53 | Ph status NR, med age NR (EST = 30s), (EST 1-3 yr), prior rx NR, mo from dx NR | Cy + TBI | CsA MTX | NR | 8 (NR) | 54-81 (NR) | 54-73 (NR) | 3 |
| Goldman et al,80 1986 | 52 | Ph+ (99%), med age = 27, 22 mo (med) from dx, prior rx NS | Cy + TBI BUS Dauno Splnx | CsA TCD | 25 | 7 (NR) | 72 (NR) | — | NR |
| Giralt et al,94 1993 | 41 | Ph status NR, med age = 32-38, mo from dx NR, 95% prior HU/BUS, 56% prior rIFN-α | TBI + other | CsA MTX “steroids” | 24 | — | 56-66 (46-79)6-164 | 46-59 (35-72)6-161 | 3 |
| Aschan et al,92 1993 | 42 | Ph+ (94%), med age = 30-39, mo from dx NR, prior rx NR | Cy + TBI + MTX | CsA TCD MTX | 60-65 | 0-62 (NR)6-162 | 38-54 (NR)6-166 | — | 6 |
| Speck et al,103 1984 | 39 | Ph+ (95%), med age = 29, 21 mo (med) from dx, 68% splnx | Cy + TBI | CsA MTX | NR (>13) | 7 (0-16) | 63 (47-79) | — | 3 |
| McGlave et al,81 1987 | 29 | Ph+, med age = 30, 14 mo (med) from dx, prior rx NR | Cy + TBI | MTX Pred Antib OKT3 | 25 | — | 64 (42-85) | — | 3 |
| Galimberti et al,84 1994 | 34 | Ph+, med age = 34, 17 mo (med) from dx, >65% prior BUS/HU/rIFN-α | BUS + Cy | CsA MTX Pred | 43 | 0 | 71 (NR) | 71 (NR) | 7 |
| Snyder et al,104 1988 | 20 | Ph+, med age = 28, 9 mo (med) from dx, variety of induction regimens | Cy + TBI | CsA Pred MTX | NR (18-54) | — | — | 55 (44-66) | NR |
| Selby et al,106 1993 | 19 | Ph status NR, med age NR, mo from dx NR, prior rx NR | Cy, TBI Vp16, Antib BCNU | CsA MTX “steroids” | 18 | — | — | 65 (NR) | 4 |
| DeWitte et al,107 1993 | 19 | Ph status NR, med age = 31, mo from dx NR, prior rx NR | Cy TBI Anthrac | CsA TCD MTX | NR | 38 (2-74) | 79 (61-97) | 49 (18-80) | 3 |
| Authors, Year . | No.6-150 . | Population Description . | Protocol . | Med f-u (mo) . | Outcomes (95% CI) for CP Patients . | Years of f-u . | |||
|---|---|---|---|---|---|---|---|---|---|
| Conditioning Regimen . | GVHD Prophylaxis . | Relapse6-151 Rate (%) . | Overall Survival mo . | Disease-Free Survival mo . | |||||
| Goldman et al,86 19936-163 | 450 | CP-Ph+, med age NR (EST = 30 s), 10 mo (med) from dx, prior rx = HU/BUS | Cy + TBI Cy + BUS | CsA MTX | NR | 9-14 (2-51)6-152 | 45-67 (26-82)6-153 | 41-65 (21-80)6-155 | 3 |
| Goldman et al,72 19886-163 | 405 | Ph status NR, med age NR, mo from dx NR, prior rx NR | “chemo” + TBI | CsA TCD MTX “steroids” | 25 | 19 (12-28) | 55 (50-60) | 46 (40-52) | 4 |
| van Rhee et al,571997 | 373 | Ph status NR, med age = 31, 42%, 1 yr from dx, prior rx NR | Cy + TBI | CsA Pred MTX | 84 | 19 (14-25) 10 (7-15) | 54 (49-59) | 47 (41-52) | 8 2 |
| Thomas et al 1986,71 1989108 | 67/190 | Ph+, med age NR (EST = 30), mo from dx NR, 19% prior BUS | Cy + TBI | CsA MTX TCD | NR | 24 (NR) | 49 (NR) 65 (NR) | — | NR |
| Devergie et al,87 1990 | 170 | Ph status NR, med age NR (EST = low 30s), 21 mo (med) from dx, 67% prior splenectomy | Cy + TBI | CsA TCD MTX | 44 | 19% (NR) | 56 (NR) | 46 (NR) | NR |
| Clift et al,68 1994 | 142 | Ph+, mean age 37-39, 71% <1 yr from dx, 93% prior rx | Cy + TBI Cy + BUS | CsA MTX | NR | NA | 80 (NR) | 68-71 (NR) | 3 |
| Beelen et al,93 1995 | 135 | Ph+, med age = 33, 16-25 mo from dx, 61% prior HU/BUS, 37% rIFN-α | Cy + TBI | CsA MTX Antibiot | 59 | 17 (7-27) | 55 (51-59) | 49 (44-54) | 5 |
| Clift et al,102 1991 | 116 | Ph+, med age NR (EST = 30s), 66% <1 yr from dx, 4-78% prior HU/BUS/rIFN | Cy + TBI | CsA MTX Pred | NR (>12) | 0-19 (0-32) 0-25 | 69-82 (57-92) 66-73 (54-86) 60-666-154 | 58-66 (NR) | 1 3 4 |
| Snyder et al,1041988 | 94 | Ph+ (99%), med age = 34, 7 mo (med) from dx, >64% prior HU, BUS, rIFN-α, other | VP-16 + TBI | CsA Pred MTX | 31 | 14 (7-26) | 73 (61-81) | 64 (52-74) | 5 |
| Wagner et al,821992 | 79 | Ph status NR, med age NR, 7-16 mo from dx, 94% prior HU, BUS, rIFN-α | Cy + TBI | CsA Mpred Cy TCD | NR | 16 (6-37)# | 52 (NR) | 54 (37-68)6-160 | 5 |
| Brodsky et al,83 1993 | 62 | Ph+, med age = 35, 10 mo (med) from dx, prior rx NR | Cy + BUS | CsA Mpred MTX | NR | 3 (2-3) | 58 (46-70) | 58 (46-70) | NR |
| Storb et al,70 1989 | 53 | Ph status NR, med age NR (EST = 30s), (EST 1-3 yr), prior rx NR, mo from dx NR | Cy + TBI | CsA MTX | NR | 8 (NR) | 54-81 (NR) | 54-73 (NR) | 3 |
| Goldman et al,80 1986 | 52 | Ph+ (99%), med age = 27, 22 mo (med) from dx, prior rx NS | Cy + TBI BUS Dauno Splnx | CsA TCD | 25 | 7 (NR) | 72 (NR) | — | NR |
| Giralt et al,94 1993 | 41 | Ph status NR, med age = 32-38, mo from dx NR, 95% prior HU/BUS, 56% prior rIFN-α | TBI + other | CsA MTX “steroids” | 24 | — | 56-66 (46-79)6-164 | 46-59 (35-72)6-161 | 3 |
| Aschan et al,92 1993 | 42 | Ph+ (94%), med age = 30-39, mo from dx NR, prior rx NR | Cy + TBI + MTX | CsA TCD MTX | 60-65 | 0-62 (NR)6-162 | 38-54 (NR)6-166 | — | 6 |
| Speck et al,103 1984 | 39 | Ph+ (95%), med age = 29, 21 mo (med) from dx, 68% splnx | Cy + TBI | CsA MTX | NR (>13) | 7 (0-16) | 63 (47-79) | — | 3 |
| McGlave et al,81 1987 | 29 | Ph+, med age = 30, 14 mo (med) from dx, prior rx NR | Cy + TBI | MTX Pred Antib OKT3 | 25 | — | 64 (42-85) | — | 3 |
| Galimberti et al,84 1994 | 34 | Ph+, med age = 34, 17 mo (med) from dx, >65% prior BUS/HU/rIFN-α | BUS + Cy | CsA MTX Pred | 43 | 0 | 71 (NR) | 71 (NR) | 7 |
| Snyder et al,104 1988 | 20 | Ph+, med age = 28, 9 mo (med) from dx, variety of induction regimens | Cy + TBI | CsA Pred MTX | NR (18-54) | — | — | 55 (44-66) | NR |
| Selby et al,106 1993 | 19 | Ph status NR, med age NR, mo from dx NR, prior rx NR | Cy, TBI Vp16, Antib BCNU | CsA MTX “steroids” | 18 | — | — | 65 (NR) | 4 |
| DeWitte et al,107 1993 | 19 | Ph status NR, med age = 31, mo from dx NR, prior rx NR | Cy TBI Anthrac | CsA TCD MTX | NR | 38 (2-74) | 79 (61-97) | 49 (18-80) | 3 |
Abbreviations: Anthrac, anthracycline; antibiot, antibiotics; BCNU, bis-chloronitrosourea; CI, confidence intervals; CP, chronic phase; CsA, cyclosporin; Cy, cyclophosphamide; dauno, daunomycin; EST, estimated median based on data provided; GVHD, graft-versus-host disease; Mpred, methylprednisolone; MTX, methotrexate; Pred, prednisone; Splnx, splenectomy; TBI, total body irradiation; TCD, T-cell depletion; Vp16, etoposide.
Number of subjects in chronic phase (preferably first chronic phase).
Explicit definitions for “relapse” generally NR.
Results for whole sample NR but stratified by prior chemotherapeutic agent and duration of disease: HU and <12, mo = 9 (2-35)%, HU and ≥12 mo = 13 (3-45)%, BUS and <12 mo = 9 (1-50)%, BUS and ≥12 mo = 14 (3-51)%.
Results for whole sample NR but stratified by prior chemotherapeutic agent and duration of disease: HU and <12, mo = 67 (48-82)%, HU and ≥12 mo = 59 (33-81)%, BUS and <12 mo = 54 (29-77)%, BUS and ≥12 mo = 45 (26-66)%.
Results for whole sample NR but stratified by prior chemotherapeutic agent and duration of disease: HU and <12 mo = 65 (47-80)%, HU and ≥12 mo = 54 (30-76)%, BUS and <12 mo = 51 (27-75)%, BUS and ≥12 mo = 41 (21-64)%.
Survival for whole sample NR; 1 yr survival = 82 (72-92)% for patients receiving 12.0 Gy v 69 (57-81) for those receiving 15.75 Gy; 3-yr survival = 73 (59-86)% for patients receiving 12.0 Gyv 66 (54-78)% for those receiving 15.75 Gy; 4-yr survival (reported only in abstract) = 60% for patients receiving 12.0 Gyv 66% for those receiving 15.75 Gy. All differences NS.
#For patients <age 30 yr. CI = 17%-80% for patients >age 30 yr.
For patients <age 30 yr. DFS = 2%-50% for patients >age 30 yr.
Results for whole sample NR. Survival for patients treated previously with rIFN-α = 56 (46-66)%, without rIFN-α = 66 (53-79)% (NS).
Results for whole sample NR. Survival for patients treated previously with rIFN-α = 46 (36-56)%, without rIFN-α = 59 (46-72)% (NS).
Results NR for whole sample but by GVHD prophylaxis: TCD (62%), MTX + CsA (20%), MTX or CsA (0%).
Results NR for whole sample but by GVHD prophylaxis: TCD (54%), MTX + CsA (59%), MTX or CsA (38%).
IBMTR: International Bone Marrow Tumor Registry.